Loading ...
Although alemtuzumab has been used to eliminated B cells , it failsto preventantibody - mediated rejection and
the production of donor - specific antibodies ( DSA ) which lead to allograft injury in part via complement activation(passive) is caused byAntibody - mediated rejection ( AMR
HLA - specific antibodies(passive) caused byAntibody mediated rejection ( AMR
593 - 600 ... efficacy of a desensitization protocol utilizing syngeneic hematopoietic stem cell transplantation ( HSCTto preventantibody - mediated rejection in VCA
The remaining patient , with fulminant hepatitis , received rituximab 3 days before LDLT ,resultingin antibody - mediated rejection
endothelial cell activation in the graft ( 37 , 43(passive) to be caused byAntibody - mediated rejection is thought
mechanisms of T cell mediated rejection ... the firstto discoverantibody mediated organ rejection
preformed or de novo donor - specific antibodies(passive) triggered byAntibody - mediated rejection
de novo DSAresultingin antibody - mediated rejection
anti - HLA antibodies that are directed towards the donor or what we call as donor - specific antibodies(passive) most often caused byantibody - mediated rejection
to be necessary in kidney transplantation ( Ktxto preventacute antibody - mediated rejection
a concise but comprehensive review of the different strategies that have been attemptedto preventthe onset of antibody - mediated rejection
Transplantation across HLA barriers and non - adherencecan resultin acute antibody - mediated rejection
preformed anti - HLA DSA in the ABO - I KTx group(passive) caused byantibody - mediated rejection ( AMR
preformed or de novo donor - specific alloantibodies ( DSA(passive) caused byAntibody - mediated rejection ( AMR
We do not know the acceptable upper limits of ABO antibody titers at the time of transplantationto preventantibody - mediated rejection
high anti - B titres of 1:1,024 preceded by peritonitis prior to transplantationcould have causedthe antibody - mediated rejection
antibodies to major histocompatibility complex(passive) can be caused byAntibody - mediated rejection
the recipient ’s anti - A / B antibody against the donor blood type(passive) caused byacute antibody - associated rejection
induced antibodies(passive) caused byacute antibody - mediated rejection
ABO incompatibility(passive) caused byacute antibody - mediated rejection
recipient ’s B - lymphocytes which produce alloantibodies against donor(passive) is caused byantibody - mediated ) type of rejection
Campath ... unableto preventantibody - mediated rejection
Concomitant immunosuppressionmust preventantibody - mediated rejection
antibodies against human leukocyte antigens ( HLA ) on graft endothelium , and non - HLA antibodies that target endothelial and epithelial proteins(passive) is caused byAntibody - mediated rejection ( AMR
a circulating , anti - HLA , donor - specificantibody.)5 Chronic allograft injury(passive) caused byantibody - mediated rejections
resensitization to ABO antigens , which occurs in high immunological risk patients(passive) caused byantibody - mediated rejection
when the antibodies were later allowed to return , the transplanted organ had developed a means of protection from these antibodiesthus preventingantibody - mediated rejection [ 5,7
antibodies carrying out ( AMR(passive) caused byantibody - mediated rejection
binding of antibodies to human leukocyte antigens(passive) is caused byAntibody - mediated rejection
antidonor antibodies(passive) caused byantibody - mediated rejection ( AMR
Removing anti - blood type antibodies by blood purification methods such as PE or plasmapheresis , splenectomy , and anti - B - cell immunosuppressants has been shownto preventacute antibody - mediated rejection
alloantibody binding and complement activation(passive) triggered byAntibody - mediated rejection
de novo donor - specific anti - human leukocyte antigen ( HLA ) antibody ( dnDSA ) productionleadingto antibody - mediated rejection
Poor adherence to immunosuppressive medicationsleadingto antibody mediated rejection ( ABMR
The challenge isto preventacute antibody - mediated rejection
She was treated with plasma exchange ( PEX ) and rituximabto preventantibody - mediated rejection ( AMR
A simplified protocol , including plasma exchange , rituximab , intravenous immunoglobin and MSCs , without splenectomy and graft local infusion , was usedto preventantibody - mediated rejection ( AMR
In these three cases of crossmatch - positive patients , rituximab failedto preventantibody - mediated rejection
their presence on a donor organwould resultin antibody mediated hyperacute rejection
chronic graft losscausingchronic graft loss
to the rapid graft lossmay have ... contributedto the rapid graft loss
early graft loss(passive) caused byearly graft loss
to heart allograft losscontributesto heart allograft loss
to graft loss ... 1 , 2leadsto graft loss ... 1 , 2
acute graft loss or shorten allograft survivalmay causeacute graft loss or shorten allograft survival
refractory graft dysfunctionfrequently causesrefractory graft dysfunction
immediate graft failurecausesimmediate graft failure
to graft failure,66leadingto graft failure,66
to Long - Term Graft Survival and Accommodation Hao Wang , Jacqueline Arp , Weihua Liu , Susan J. Faas , Jifu Jiang , David R. Gies , Siobhan Ramcharran , Bertha Garcia , Robert Zhong and Russell P. Rother J Immunol October 1 , 2007Leadingto Long - Term Graft Survival and Accommodation Hao Wang , Jacqueline Arp , Weihua Liu , Susan J. Faas , Jifu Jiang , David R. Gies , Siobhan Ramcharran , Bertha Garcia , Robert Zhong and Russell P. Rother J Immunol October 1 , 2007
no graft failure in ABO - I recipientscausedno graft failure in ABO - I recipients
to allograft loss ... despite pretransplantation and post - transplantation de- sensitization therapies and adequate post - trans- plantation immunosuppressionleadsto allograft loss ... despite pretransplantation and post - transplantation de- sensitization therapies and adequate post - trans- plantation immunosuppression
not only to hyperacute and acute but alsocontributingnot only to hyperacute and acute but also
to chronic kidney transplant rejection through multiple mechanisms and is a major contributor of late graft loss Recognize how advances in understanding rejection at the molecular level may improve detection and diagnostics Identify treatment options for antibody - mediated rejection E. Steve Woodle , MD , FACS , Chief of Transplant Surgery , University of Cincinnati E. Steve Woodle , MD , FACS , is Professor of Surgery and Chief for the Division of Transplant Surgery at the University of Cincinnati College of Medicinecan leadto chronic kidney transplant rejection through multiple mechanisms and is a major contributor of late graft loss Recognize how advances in understanding rejection at the molecular level may improve detection and diagnostics Identify treatment options for antibody - mediated rejection E. Steve Woodle , MD , FACS , Chief of Transplant Surgery , University of Cincinnati E. Steve Woodle , MD , FACS , is Professor of Surgery and Chief for the Division of Transplant Surgery at the University of Cincinnati College of Medicine
graft dysfunction and chronic rejection ... the leading cause of death among transplant patientscan causegraft dysfunction and chronic rejection ... the leading cause of death among transplant patients
AMR)Antibodies directed against donor antigencan causeAMR)Antibodies directed against donor antigen
in severe allograft dysfunctionresultingin severe allograft dysfunction
to loss of the grafted kidneyleadsto loss of the grafted kidney
to liver damageleadingto liver damage
in allograft failuremay resultin allograft failure
subclinical injury(passive) caused bysubclinical injury
to chronic lung allograft dysfunctionmay leadto chronic lung allograft dysfunction
60 percent of all transplanted kidney failurescauses60 percent of all transplanted kidney failures
significantlycan ... influencesignificantly
postttansplant proteinuriacan causepostttansplant proteinuria
from activation of complement by C1q- and MBLresultingfrom activation of complement by C1q- and MBL
the loss of a transplanted kidney in about 30 per cent of patientstriggersthe loss of a transplanted kidney in about 30 per cent of patients
the incidence of dysfunction(passive) caused bythe incidence of dysfunction
to proteinuria [ 13could leadto proteinuria [ 13
to the evolution of the lesioncan ... contributeto the evolution of the lesion